|
|
Line 3: |
Line 3: |
| <StructureSection load='5n6c' size='340' side='right'caption='[[5n6c]], [[Resolution|resolution]] 2.30Å' scene=''> | | <StructureSection load='5n6c' size='340' side='right'caption='[[5n6c]], [[Resolution|resolution]] 2.30Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[5n6c]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5N6C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5N6C FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5n6c]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5N6C OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5N6C FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene>, <scene name='pdbligand=TLA:L(+)-TARTARIC+ACID'>TLA</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PHGDH, PGDH3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene>, <scene name='pdbligand=TLA:L(+)-TARTARIC+ACID'>TLA</scene></td></tr> |
- | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Phosphoglycerate_dehydrogenase Phosphoglycerate dehydrogenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.95 1.1.1.95] </span></td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5n6c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5n6c OCA], [https://pdbe.org/5n6c PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5n6c RCSB], [https://www.ebi.ac.uk/pdbsum/5n6c PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5n6c ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5n6c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5n6c OCA], [http://pdbe.org/5n6c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5n6c RCSB], [http://www.ebi.ac.uk/pdbsum/5n6c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5n6c ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| == Disease == | | == Disease == |
- | [[http://www.uniprot.org/uniprot/SERA_HUMAN SERA_HUMAN]] Defects in PHGDH are the cause of phosphoglycerate dehydrogenase deficiency (PHGDH deficiency) [MIM:[http://omim.org/entry/601815 601815]]. It is characterized by congenital microcephaly, psychomotor retardation, and seizures. | + | [https://www.uniprot.org/uniprot/SERA_HUMAN SERA_HUMAN] Defects in PHGDH are the cause of phosphoglycerate dehydrogenase deficiency (PHGDH deficiency) [MIM:[https://omim.org/entry/601815 601815]. It is characterized by congenital microcephaly, psychomotor retardation, and seizures. |
| + | == Function == |
| + | [https://www.uniprot.org/uniprot/SERA_HUMAN SERA_HUMAN] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 27: |
Line 28: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Phosphoglycerate dehydrogenase]]
| + | [[Category: Basle A]] |
- | [[Category: Basle, A]] | + | [[Category: Cano C]] |
- | [[Category: Cano, C]] | + | [[Category: Curtin NJ]] |
- | [[Category: Curtin, N J]] | + | [[Category: Noble MEM]] |
- | [[Category: Noble, M E.M]] | + | [[Category: Tucker J]] |
- | [[Category: Tucker, J]] | + | [[Category: Unterlass JE]] |
- | [[Category: Unterlass, J E]] | + | |
- | [[Category: Dehydrogenase]]
| + | |
- | [[Category: Enzymology]]
| + | |
- | [[Category: Oxidoreductase]]
| + | |
- | [[Category: Serine metabolism]]
| + | |
| Structural highlights
Disease
SERA_HUMAN Defects in PHGDH are the cause of phosphoglycerate dehydrogenase deficiency (PHGDH deficiency) [MIM:601815. It is characterized by congenital microcephaly, psychomotor retardation, and seizures.
Function
SERA_HUMAN
Publication Abstract from PubMed
Cancer cells reprogram their metabolism and energy production to sustain increased growth, enable metastasis and overcome resistance to cancer treatments. Although primary roles for many metabolic proteins have been identified, some are promiscuous in regards to the reaction they catalyze. To efficiently target these enzymes, a good understanding of their enzymatic function and structure, as well as knowledge regarding any substrate or catalytic promiscuity is required. Here we focus on the characterization of human 3-phosphoglycerate dehydrogenase (PHGDH). PHGDH catalyzes the NAD(+)-dependent conversion of 3-phosphoglycerate to phosphohydroxypyruvate, which is the first step in the de novo synthesis pathway of serine, a critical amino acid for protein and nucleic acid biosynthesis. We have investigated substrate analogues to assess whether PHGDH might possess other enzymatic roles that could explain its occasional over-expression in cancer, as well as to help with the design of specific inhibitors. We also report the crystal structure of the catalytic subunit of human PHGDH, a dimer, solved with bound cofactor in one monomer and both cofactor and L-tartrate in the second monomer. In vitro enzyme activity measurements show that the catalytic subunit of PHGDH is still active and that PHGDH activity could be significantly inhibited with adenosine 5'-diphosphoribose.
Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH).,Unterlass JE, Wood RJ, Basle A, Tucker J, Cano C, Noble MME, Curtin NJ Oncotarget. 2017 Nov 6;8(61):104478-104491. doi: 10.18632/oncotarget.22327., eCollection 2017 Nov 28. PMID:29262655[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Unterlass JE, Wood RJ, Basle A, Tucker J, Cano C, Noble MME, Curtin NJ. Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget. 2017 Nov 6;8(61):104478-104491. doi: 10.18632/oncotarget.22327., eCollection 2017 Nov 28. PMID:29262655 doi:http://dx.doi.org/10.18632/oncotarget.22327
|